AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00503750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre operativeTrastuzumab
Description: Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.~As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52.
Study NCT00503750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABI-007 (Abraxane)
Description: ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
Study NCT00503750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
Study NCT02123134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATX-101
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
Study NCT02123134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study NCT03827408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam group (MDZ)
Description: IV Ampules of Dormicum 15mg/ 3ml, Hoffman-La Rouche Ltd., Basel, Switzerland
Study NCT02518321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technology-Assisted Toileting
Study NCT03827408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (DEX)
Description: IV Ampules of Precedex 4mcg/ml, Hospira. Inc., Lake Forest,IL USA.
Study NCT03827408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Midazolam and Dexmedetomidine (MDZ/DEX)
Description: Combination of Nebulized solution of 0.3 mg/kg Midazolam, and 3µg/kg Dexmedetomidine respectively.(
Study NCT03936114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART
Description: SMART program mindfulness training program
Study NCT02075112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soy isoflavone
Description: Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
Study NCT02075112 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
Study NCT02075112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
Study NCT02919644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells loaded with autologous tumour homogenate
Description: Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
Study NCT02919644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
Study NCT00726947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging of Acute DVT
Study NCT00726947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound imaging of Chronic DVT
Study NCT04077567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-152
Description: 30mg,80mg
Study NCT04439136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib Dimaleate
Description: Given PO
Study NCT02050061 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: compression stocking
Description: study the impact of compression stocking
Study NCT01755234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
Study NCT01755234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
Study NCT00248495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00248495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV
Study NCT00248495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Metastasis prevention/control
Study NCT00248495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergoing tissue removal
Study NCT00248495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Tumor Reduction
Study NCT01772628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classroom-based component
Description: Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
Study NCT01772628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STI/HIV prevention education
Description: For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration.
Study NCT01772628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Homework assignment component
Description: This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
Study NCT01772628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting component
Description: Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
Study NCT03812380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EffCaMgCit
Description: Each sachet of EffCaMgCit will contain 19 meq or 380 mg calcium, 10 meq (122 mg) magnesium, and 50 meq total citrate.
Study NCT03812380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each sachet of Placebo will contain microcrystalline cellulose, but no calcium, magnesium or citrate. Placebo will be added to 6 oz water for 1-2 minutes, to be dissolved/suspended before swallowing. The placebo will contain 400 units of vitamin D.
Study NCT05217277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Humans ELISA kits
Description: ELISA (enzyme-linked immunosorbent assay) is a plate-based assay technique designed for detecting and quantifying soluble substances such as peptides, proteins, antibodies, and hormones.~The saliva of the patients included in the study will be examined with ELISA kits after they are taken.
Study NCT02919774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POMA
Description: Pomaglumetad (POMA) is a mGluR 2/3 partial agonist
Study NCT02919774 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo tablets
Study NCT01826396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Comparison of standard and high dose irinotecan
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287
Description: U3-1287: 18 mg/kg administered intravenously once every three weeks
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1287
Description: The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel: 175 mg/m\^2 administered intravenously once every three weeks
Study NCT00842985 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: drug condition
Description: Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
Study NCT01512199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
Study NCT01962441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily
Study NCT01962441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01962441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: 180 µg administered via subcutaneous injection once weekly
Study NCT00651781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: 2 times per week of Velcade administration.
Study NCT02525653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Study NCT02525653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Study NCT03381521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided nerve hydrodissection
Description: Ultrasound-guided nerve hydrodissection with 10cc normal saline between carpal tunnel and median nerve.
Study NCT03381521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided nerve hydrodissection
Description: Ultrasound-guided nerve hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
Study NCT03381521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The ultrasound was used to measure cross-sectional area and injection guidance
Study NCT03381521 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The ultrasound was used to measure cross-sectional area and injection guidance
Study NCT03381521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: The normal saline was used for injection solution
Study NCT03381521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: The normal saline was used for injection solution
Study NCT02302768 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenomethionine
Study NCT02302768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00423657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftaroline
Description: 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
Study NCT00423657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin plus aztreonam
Description: vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
Study NCT00423657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
Study NCT04042220 — intervention group
Intervention type: DRUG
Intervention: Glucocorticoids
Description: Effect of glucocorticoids (which are often prescribed for cerebral edema) on clinical outcome
Study NCT03296514 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MBSR
Description: Eight week class on MBSR in addition to an orientation class and a half day retreat
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: 10 mg/kg single dose IV or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: 3 mg/kg single dose IV or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: For atopic patient:10 mg/kg single IV dose or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: For atopic patient: 3 mg/kg single dose SC or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: 0.3 mg/kg single dose IV or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: 0.1 mg/kg single dose Intravenously (IV) or matching placebo
Study NCT01081691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CNTO 5825
Description: 1 mg/kg single dose IV or matching placebo
Study NCT03658122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-Child Care
Description: Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
Study NCT03658122 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parent-Child Care
Description: Parent-Child Care (PC-CARE) is a 6-week parenting intervention for children aged 1-10 years and their caregivers. This behavioral intervention involves weekly behavioral assessments, teaching of new skills, in-the-moment practice using the new skills, and discussion of how to incorporate skills at home.
Study NCT03206216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diode Laser fiber type Selective Stimulator (DLss)
Description: A laser device to assess pain sensitivity to stimulation
Study NCT03206216 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser fiber type Selective Stimulator (DLss)
Description: A laser device to assess pain sensitivity to stimulation
Study NCT03965975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lab Gold Standard
Description: First intervention (assigned to the All participants arm).
Study NCT03965975 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: S-There
Description: Second intervention (assigned to the All participants arm).
Study NCT02513121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary modification
Description: The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
Study NCT04673214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group A of Azithromycin / Ivermectin / Ribaroxaban / Paracetamol to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Study NCT04673214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin / Ribaroxaban / Paracetamol
Description: In the patient with the presence of COVID-19 confirmed by the PCR-COVID-19 positive test, the drug is randomly assigned to belong to group B of Azithromycin / Ribaroxaban / Paracetamol, to be followed for 14 days by video call (approximately 15 to 20 min per day) to the patient and the presence or absence of clinical symptoms, adverse reactions being recorded daily
Study NCT00743002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TT223 with Metformin and/or TZD
Description: Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
Study NCT00743002 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with Metformin and/or TZD
Description: Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
Study NCT03897959 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Kohli vs Foley catheter
Description: Alternative suprapubic catheter used for bladder drainage.
Study NCT03690817 — intervention group
Intervention type: BEHAVIORAL
Intervention: RBANS-H, virtual Morris Water Maze
Description: Cognitive tasks for respectively: general cognition and spatial cognition
Study NCT04344808 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic navigation system
Description: The navigation system allows clinicians, using a specific software, to visualize the position of the surgical drill (tip location and shaft axis direction) on the reconstructed 3D image of the pre-acquired CBCT. The software guides the surgeon, in real-time, to the preoperative planned position.
Study NCT04344808 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand implant placement
Description: Dental implants will be placed without any guidance once a virtually planning of the ideal position on the CBCT is done
Study NCT03196908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink Brand 1
Description: Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
Study NCT03196908 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink Brand 2
Description: Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
Study NCT03196908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lime juice, water, and cherry flavoring
Study NCT04294121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food marketing on product packaging
Description: Participants will be exposed to product packages displaying varying child- and parent-appealing marketing techniques and different degrees of marketing power
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 1
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 1
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 2
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 2
Description: fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seqeunce 3
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seqeunce 3
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequence 4
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
Study NCT01353404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sequence 4
Description: fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral